Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Alopexx Collaborates with Bharat Biotech on Anti-Microbial Vaccine AV0328
Details : The collaboration aims for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low and lower middle-income countries.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Biotech Consortia
Deal Size : Undisclosed
Deal Type : Financing
Alopexx Announces Investment from Biotech Consortia, Inc.
Details : The investment from BCI will be crucial for the advancement of AV0328, a synthetic vaccine designed to target poly N-acetyl glucosamine, and all clinical programs at Alopexx.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
September 06, 2024
Lead Product(s) : AV0328
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Biotech Consortia
Deal Size : Undisclosed
Deal Type : Financing
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma
Details : The deal facilitates development and commercialization of DI-Leu16-IL2 in China and other parts of Asia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
March 03, 2020
Lead Product(s) : F598
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : F598 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neisseria gonorrhoeae.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 19, 2017
Lead Product(s) : F598
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AV0328
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of AV0328 Administered to Healthy Adult Volunteers
Details : AV0328 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 03, 2016
Lead Product(s) : AV0328
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DI-Leu16-IL2 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 02, 2014
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
Details : DI-Leu16-IL2 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 11, 2013
Lead Product(s) : DI-Leu16-IL2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable